Roche's new cancer drugs cushion first half
This article was originally published in Scrip
Executive Summary
Roche has reported a solid set of first half results with 6% sales growth (at CER) to CHF46.8bn ($51.9bn), which was in line with analyst consensus expectations. Core EPS growth was ahead of sales at 10% to reach CHF14.27bn.